All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @janessgg on TikTok · 166s|Watch on TikTok

@janessgg's tirzepatide Q&A invitation, fact-checked

Janeth Salazar

TikTok creator

383.1K viewsWatch on TikTok

Quick answer

Tirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). The SURMOUNT-1 trial demonstrated up to 22.5% weight loss over 72 weeks, making it one of the most effective weight loss medications available.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded TirzepatideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Tirzepatide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @janessgg's tirzepatide Q&A invitation, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

Compounded Tirzepatide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Claim path

Keep researching this tirzepatide video claims cluster

Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@janessgg's tirzepatide Q&A invitation, fact-checked" from Janeth Salazar. We read the clip as a GLP-1 social video fact-checks claim about Compounded Tirzepatide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Tirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound).

The reason this review is not generic is the source wording and the canonical claim label "glp1 deja tu pregunta beb mounjaro tirzepatide desbalanceh." In this clip, the useful excerpt is: "Deja tu pregunta bebé 🩷" That wording changes the review because it points to Compounded Tirzepatide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Tirzepatide Once Weekly for the Treatment of Obesity (2022), Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (2024), and Tirzepatide for Obesity Treatment and Diabetes Prevention (2025), plus the creator's own wording. Compounded Tirzepatide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

The drug is FDA-approved for diabetes and obesity, not for treating hormonal imbalances
People who land here are usually comparing the Compounded Tirzepatide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Tirzepatide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Tirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound).

FormBlends verdict

Compounded Tirzepatide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Tirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). The SURMOUNT-1 trial demonstrated up to 22.5% weight loss over 72 weeks, making it one of the most effective weight loss medications available.
  • Tirzepatide achieved up to 22.5% weight loss in the SURMOUNT-1 trial over 72 weeks
  • The drug is FDA-approved for diabetes and obesity, not for treating hormonal imbalances

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.

Review Compounded Tirzepatide

What You'll Learn

  • Tirzepatide achieved up to 22.5% weight loss in the SURMOUNT-1 trial over 72 weeks
  • The drug is FDA-approved for diabetes and obesity, not for treating hormonal imbalances
  • Weight loss from tirzepatide may indirectly improve some hormone markers
  • About 10% of clinical trial participants stopped the medication due to side effects
  • Medical questions about prescription drugs should be directed to healthcare providers, not social media
  • The medication costs approximately $1,000 monthly without insurance coverage
  • Tirzepatide requires specific BMI or diabetes criteria for appropriate prescription

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What does this video actually claim?

This TikTok from @janessgg (Janeth Salazar) doesn't make specific medical claims about tirzepatide. Instead, it's essentially an invitation for viewers to ask questions about Mounjaro/tirzepatide and hormonal imbalance. The caption translates to "Leave your question baby" with hashtags linking tirzepatide to hormone issues.

The video format suggests she's positioning herself as someone who can answer questions about this GLP-1/GIP dual agonist. With 383,000 views, it's clearly landing with people curious about the medication.

While she doesn't make overt medical claims here, the hashtag combination implies she'll discuss tirzepatide's effects on hormones, which deserves scrutiny.

Does tirzepatide actually affect hormones?

Yes, but not in the way most social media users think. Tirzepatide works by mimicking GLP-1 and GIP hormones, which regulate blood sugar and slow gastric emptying. The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) showed 22.5% weight loss at the highest dose over 72 weeks.

Weight loss itself can improve hormone profiles. The same trial found improvements in insulin sensitivity and reductions in inflammatory markers. But tirzepatide isn't prescribed specifically for "hormonal imbalance," a term that's medically vague anyway.

Some users report menstrual changes, likely due to rapid weight loss rather than direct hormonal effects. The medication can also affect thyroid hormone levels in some patients, which is why doctors monitor TSH levels during treatment.

What's the problem with hormone-focused messaging?

Framing tirzepatide as a hormone fix misleads people about what the drug actually does. It's FDA-approved for type 2 diabetes (as Mounjaro) and obesity (as Zepbound), not for treating hormonal imbalances.

This messaging can attract people who don't meet clinical criteria for the medication. The drug costs around $1,000 monthly without insurance and carries real risks including gastroparesis, pancreatitis, and severe gastrointestinal effects.

Clinical trials excluded people with certain hormone-related conditions. The SURMOUNT studies didn't specifically recruit people with PCOS, thyroid disorders, or other hormonal issues that TikTok users often discuss.

What should people actually know about tirzepatide?

Tirzepatide is remarkably effective for weight loss in appropriate candidates. The SURMOUNT-1 data showed average weight reductions of 16.0%, 21.4%, and 22.5% at 5mg, 10mg, and 15mg doses respectively. These results surpass most other weight loss medications.

But it's not a hormone treatment. Doctors prescribe it based on BMI criteria (30+ or 27+ with comorbidities) or diabetes status, not because someone thinks their hormones are "imbalanced."

Side effects are common and can be serious. About 10% of participants in major trials discontinued due to gastrointestinal issues. The medication requires careful medical supervision and isn't appropriate for everyone who wants it.

Should you ask medical questions on TikTok?

Absolutely not for serious health decisions. While @janessgg might share her personal experience, individual responses to tirzepatide vary dramatically. What works for one person might cause severe side effects in another.

The comment sections of these videos often become informal medical consultations, which is dangerous. People share dosing advice, discuss side effects, and make treatment recommendations without any medical training or knowledge of individual health histories.

If you're interested in tirzepatide, talk to a healthcare provider who can review your medical history, current medications, and determine if you're an appropriate candidate. That conversation should happen in a clinical setting, not a TikTok comment thread.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Janeth Salazar · TikTok creator

383.1K views on this video

Deja tu pregunta bebé 🩷 #mounjaro #tirzepatide #desbalancehormonal

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about tirzepatide achieved up to 22.5% weight loss in the surmount-1?

Tirzepatide achieved up to 22.5% weight loss in the SURMOUNT-1 trial over 72 weeks

What does the video say about the drug?

The drug is FDA-approved for diabetes and obesity, not for treating hormonal imbalances

What does the video say about weight loss from tirzepatide may indirectly improve some hormone markers?

Weight loss from tirzepatide may indirectly improve some hormone markers

What does the video say about about 10% of clinical trial participants stopped the medication due?

About 10% of clinical trial participants stopped the medication due to side effects

What does the video say about medical questions about prescription drugs should be directed to healthcare?

Medical questions about prescription drugs should be directed to healthcare providers, not social media

What does the video say about the medication costs approximately $1,000 monthly without insurance coverage?

The medication costs approximately $1,000 monthly without insurance coverage

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Janeth Salazar, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.